Robert L. Coleman, MD, FACOG, FACS

Articles

Dr. Coleman on the Potential of Tisotumab Vedotin in Cervical Cancer

January 20th 2021

Robert L. Coleman, MD, FACOG, FACS, discusses the potential of tisotumab vedotin in cervical cancer.

Dr. Coleman on Moving Immunotherapy Into Earlier Treatment Lines in Cervical Cancer

January 18th 2021

Robert L. Coleman, MD, FACOG, FACS, discusses the potential to move immunotherapy into earlier lines of treatment in cervical cancer.

Dr. Coleman on the Clinical Implications of the innovaTV 204 Trial in Cervical Cancer

September 21st 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the clinical implications of the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 trial in women with previously treated recurrent or metastatic cervical cancer.

Dr. Coleman on Recent Advances and Remaining Questions in Ovarian Cancer

May 5th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses recent advances made in the treatment of patients with ovarian cancer and remaining questions regarding the role of immunotherapy.

Dr. Coleman on Recent Advancements Made in Cervical Cancer Treatment

May 2nd 2020

Robert L. Coleman, MD, FACOG, FACS, discusses recent advancements made in the cervical cancer space.

Dr. Coleman on Results of the VELIA Trial in Ovarian Cancer

March 12th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the results of the phase III VELIA trial examining veliparib in combination with chemotherapy in ovarian cancer.

Dr. Coleman on the VELIA Trial Impact on Ovarian Cancer Practice

March 11th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the impact of the VELIA trial on ovarian cancer practice.

Dr. Coleman on the Safety Profile of Veliparib in Ovarian Cancer

February 22nd 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the safety profile of veliparib examined in the VELIA trial looking at patients with high-grade serous ovarian cancer.

Dr. Coleman on the Use of Veliparib in Ovarian Cancer

January 29th 2020

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the use of veliparib in ovarian cancer.

Dr. Coleman on Implications of the VELIA Trial in Ovarian Cancer

January 21st 2020

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the implications of the phase III VELIA trial in ovarian cancer.

x